Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Escalating Doses of Carfilzomib With Hyper-CVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

NCT02293109 is registered in ClinicalTrials.gov with Mehrdad Abedi, MD as lead sponsor.

NCT NCT02293109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02293109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Escalating Doses of Carfilzomib With Hyper-CVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Lead sponsor
Mehrdad Abedi, MD
Phase
Phase 1
Overall status
Completed
Start date
December 17, 2015
Completion date
January 11, 2018
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

contiguous stage ii adult lymphoblastic lymphoma, noncontiguous stage ii adult lymphoblastic lymphoma, stage i adult lymphoblastic lymphoma, stage iii adult lymphoblastic lymphoma, stage iv adult lymphoblastic lymphoma, untreated adult acute lymphoblastic leukemia